Survival analysis in prognostic studies has usually relied on KaplanMeier and/or multivariable Cox proportional hazard models. Earlier studies suggesting the superiority of 24 h ambulatory blood pressure (ABP) over and above office blood pressure (BP), and the incremental prognostic value of night-time ABP are no exception. One of the most important limitations of conventional survival analysis is the censoring of the survival time at the end of the observation period, for subjects not experiencing an event of interest. During the last decade, methodologies integrating the concept of competing risk analysis have gained popularity for remediation of this limitation. For prognosis-oriented research questions, Fine and Gray developed a sub-distribution hazard model. 1, 2 For more aetiology-oriented research questions, multivariable cause-specific proportional hazard (sometimes termed cause-specific Cox regression) models have been recommended. 3 Applying competing risk analysis is precisely what Mortensen et al. 4 have done in their analysis of the large International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO). 5, 6 In addition, they developed a prediction model of 10 year person-specific absolute risks of cardiovascular (CV) mortality and CV events. It is a retrospective multi-centre analysis on six cohorts of subjects representing the general population of various countries: Copenhagen (Denmark), Ohasama (Japan), Noorderkempen (Belgium), Uppsala (Sweden), Montevideo (Uruguay), and Maracaibo (Venezuela). On a total of 10 425 subjects, 7929 were considered to have adequate BP readings and sufficient data on covariates and outcome to be included. Mean age was 57 years, mean body mass index was 26 kg/m 2 , and mean office systolic BP was 135 mmHg. Prevalence of diabetes and treated hypertension was 9 and 23%, respectively. Of note, mean systolic BP was 147 mmHg in Uppsala and 171 mmHg (!) in Maracaibo, the other means being around 130 mmHg. Minimum median follow-up was 9.1 years. During the follow-up period, a total of 563 participants died from CV events and 758 died from non-CV events. Further, a total of 1173 were diagnosed with a fatal or non-fatal CV event. Without doubt, it is a large database with long and detailed follow-up. For the present analyses, the authors removed six of the original studies included in the IDACO database, presumably because of a too short follow-up period. Earlier, in part of the original IDACO database (Belgium, Denmark, Japan, and Sweden), ABP proved superior to office BP in predicting CV but not total and non-CV mortality. 5 When two correlated variables such as ABP and office BP are entered in a classical Cox regression model, one of them may appear more important than the other. The background idea of the study under scrutiny is that a somewhat higher hazard ratio for an endpoint (as usually occurs for ABP vs. office BP) does not necessarily translate into better long-term prediction for an individual person (personspecific absolute risk models). It is a well-accepted proposition. The long-term prediction of a person's risk not only depends on the association of BP with CV events but also on the competing risk of non-CV mortality. In the study of Mortensen et al.
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, cause-specific Cox regression models failed to show clinically relevant added value for 24 h ABP in 10 year risk prediction in a model containing office and 24 h ABP next to common risk indicators. Moreover, night-time BP did not improve 10 year prediction obtained from daytime measurements. For an otherwise healthy population, sufficient prognostic accuracy for CV risks can be achieved with office BP. The interpretation of aetiological research in the presence of competing risks should bear in mind that, because of competing events handled as censored observations, the number of patients at risk during follow-up decreases (removal from the remaining risk sets). The cause-specific Cox regression hazard ratios should therefore be viewed rather as hazard ratios for those individuals not (yet) experiencing the event of interest or a competing event. The authors correctly formulated the implication in their supplemental section: 'Consequently, the cause-specific hazard ratio of the cardiovascular endpoint does not have a direct interpretation on the absolute risk of the cardiovascular endpoint. ' The introduction of competing risk analyses is undoubtedly a valuable addition to the armamentarium of survival analysis. One of the major advantages is that cause-specific proportional hazard models easily fit with classical dedicated software. The present investigation questions and nearly nullifies the incremental benefits of performing 24 h ABP for predicting CV risk. These conclusions, with potentially far-reaching consequences, should be carefully examined. Moreover, competing risk analyses that are integrated into absolute risk prediction models need to be interpreted in terms of their strengths and weaknesses. Of importance, the cause-specific Cox regression models confirmed most of the trends for 24 h ABP, albeit with lower confidence, obtained for CV mortality and all CV events in the landmark studies, which all blatantly neglected competing risk analyses because they were unpopular and not standard in commercial statistical packages at that time. However, for night-time BP, the contrast between the classical and cause-specific Cox regression approaches is striking. The data by Mortensen et al. 4 do not corroborate with an earlier finding in hypertensive patients showing that night-time ABP is a better predictor of outcome than daytime ABP. 7 Of interest, cause-specific hazard functions of competing risk (i.e. non-CV mortality) are created using the information available by study design, which essentially focuses on CV risks in many cases. This might be a limitation. It is well known among statisticians that even highly significant classical Cox regression hazard ratios may fail to translate into significant improvements in prediction models for long-term prognosis in terms of absolute risks. Large hazard ratios are required to improve risk prediction models. 8, 9 Given the published modest crude estimates 10 , the a priori likelihood that 24 h ABP would improve 10 year personspecific absolute risks of fatal and non-fatal CV events in a clinically relevant manner was low if not very low. The authors' findings are no surprise and are in line with the expectation that there is no compelling need in primary prevention to introduce a second BP-related parameter next to systolic BP for the assessment of CV risk. In the same way, it is highly unlikely that adding a parameter from 24 h ABP recordings to the usual set of SCORE (Systematic Coronary Risk Evaluation) parameters 11, 12 (SCORE that already includes office BP)
would dramatically improve the model. By the same token, it has been difficult for any tested biomarker to increase the predicting capacity of SCORE in a clinically relevant way. Even most genetic testing assays have so far failed to achieve this. The question may arise whether current standards and recommendations for measuring office BP still meet current quality requirements and whether there is room for improvement by adapting to recent evolutions in technology. In the present study, office BP was measured with a standard mercury sphygmomanometer or an automatic device. For each person, at least two office BP measurements were recorded. The measurements were recorded after the person had rested in the sitting or supine position for at least 2 min (Ohasama), 5 min (Copenhagen, Noorderkempen, Montevideo, and Maracaibo), or 10 min (Uppsala). There are obviously distinct procedures in the study. It is uncertain whether methodological differences have influenced the predictive information of BP measurements. The procedures of BP measurement used in the study certainly are already better standardized and more representative than the 'casual' BP measurement performed by most general practitioners and practising cardiologists. However, there is still room for improvement, even in the setting of observational cohorts and interventional trials. The SPRINT (Systolic Blood Pressure Intervention Trial) Investigators 13 reopened a long-standing debate on protocols, with unattended fully-automated stand-alone BP measurements as a candidate option in future trials and clinical practice. The protocol in SPRINT included a 5 min rest, used automated office BP measurement, and measured BP three times unobserved. The BP measurement technique in SPRINT differed from previous studies in one key element: other people were out of the room during measurements and during the entire resting period prior to measurement. The SPRINT Investigators tried avoiding the alert reaction or 'white coat' effect. This is critically important, since systolic BP when measured this way may be 5-10 mmHg lower than when measured with a manual instrument 14 , or even when patients are being observed or disturbed by talking or by a room that is not quiet. The lower BP level targets suggested by the SPRINT investigators 15 are beyond the scope of the present editorial. The debate is related to the optimal way of measuring BP in clinical practice. We completely agree with the viewpoint, expressed for example by Daniel Levy from the Framingham Heart study, that the SPRINT BP methodology or an analogous procedure should become the new standard. The topic is highly controversial but the debate is ongoing. Using contemporary technology to substitute for good old BP measurement techniques should not necessarily be viewed as a deadly sin, although it would unavoidably create a lot of work regarding re-standardization and resetting cut-off values. A reappraisal of the added value (if any left) of multiple pressure measurements over 24 h beyond this optimized standard in terms of classical outcomes would become unavoidable. The a priori likelihood for a 24 h ABP parameter to significantly improve risk prediction models including optimized office BP readings and accounting for competing risks would even further decrease. In observational and interventional multi-centre studies, every investigator should be aware that the benefits of an increased number of observations can be offset by an increased inhomogeneity of the data, albeit that there was no statistically significant heterogeneity in the study under investigation. This balance should be carefully assessed each time. When analyses included both office BP and ABP, with CV mortality or CV events as endpoint (Supplementary Table 1 and 2 from ref. 4 ), some of the cohorts revealed a significant prognostic benefit while others did not or did it to a lesser extent. Significant results are sometimes diluted. The meta-averages remained significant for both treated and untreated subjects, but were insufficiently high to result in a meaningful, better subsequent prediction.
In conclusion, the important retrospective study by Mortensen et al. 4 conducted in a large and reliable multi-centre database questions the added clinical value of 24 h systolic ABP relative to office systolic BP, and of night-time ABP relative to daytime ABP for the prediction of 10 year person-specific absolute risks of fatal and nonfatal CV events. The 'negative' conclusions are valid. It cannot be denied that the IDACO database represents an invaluable amount of work and that both the high quality of the data and the large number of inclusions guarantee sound conclusions. Nonetheless, it has to be noted that the likelihood of any newcomer measurement, closely related to an already settled one, improving prediction of the personspecific absolute CV risk in a clinically relevant way is low. Such a venture inevitably is a 'Sisyphus' tale. Office systolic BP and 24 h ABP and are no exceptions. Appropriate use of newer statistical methods, including competing risk analysis, may have contributed further to the very poor added value for 10 year risk prediction by 24 h ABP in models containing both office and 24 h ABP. The present findings nevertheless do not imply that, at the time being, 24 h ABP would not be useful for diagnosis or for evaluation of treatment.
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